May 24, 2024
Sarcopenia Treatment Market

Sarcopenia Treatment is Expected to be Flourished by Increasing Geriatric Population Globally

Sarcopenia refers to the loss of skeletal muscle mass and strength associated with aging. Some of the key products associated with sarcopenia treatment include protein supplements, vitamin D & calcium supplements, and exercise therapy equipment. Protein supplements help in increasing muscle protein synthesis while vitamin D & calcium helps in maintaining bone and muscle health. Exercise therapy equipment like treadmills, stationary bikes and weights are used to perform resistance and aerobic exercises crucial for sarcopenia management.

The global sarcopenia treatment market is estimated to be valued at US$ 3.47 Billion in 2024 and is expected to exhibit a CAGR of 9.5% over the forecast period 2024-2031, as highlighted in a new report published by Coherent Market Insights.

Market Dynamics

The increasing geriatric population globally is one of the major drivers of the sarcopenia treatment market. As per United Nations reports, the number of people aged 65 years or above is projected to grow from 727 million in 2020 to 1.5 billion in 2050 worldwide. This burgeoning geriatric demographic is more susceptible to sarcopenia due to age related muscle loss. According to latest WHO data, over 1.5 billion adults aged 65 and older are projected to be affected by sarcopenia by 2050. This massive patient pool requiring sarcopenia management will propel the demand for protein supplements, vitamin supplementation and exercise therapy equipment over the forecast period. Another important driver is increasing awareness about sarcopenia and availability of its treatment options. Various healthcare organizations and government bodies are conducting health campaigns to educate people about sarcopenia prevention and management through diet, exercise and supplementation. This has led more individuals seek formal diagnosis and treatment adoption.

Segment Analysis

The sarcopenia treatment market can be segmented into products, therapy and distribution channel. By products, the market is divided into drugs and supplements. Drugs dominates the market as there are prescription drugs available to treat sarcopenia. The commonly prescribed drugs are Megestrol acetate and testosterone replacement therapy. Supplements segment is expected to witness strong growth due to rising preference for nutritional supplements.

By therapy, the market is classified into resistive exercise therapy, protein supplementation therapy, hormone replacement therapy and vitamin D and calcium supplementation. Resistive exercise therapy dominates the market as exercising is the first line of defense against sarcopenia. Protein supplementation therapy is expected to witness high growth as dietary protein intake is essential for muscle mass maintenance.

By distribution channel, the market is bifurcated into hospital pharmacies, retail pharmacies and online stores. Hospital pharmacies dominate the market as most patients are treated and prescribed drugs on outpatient basis in hospitals. Online stores segment is poised to grow at fastest pace due to increasing penetration of e-commerce.

PEST Analysis

Political: Governments globally are raising awareness about sarcopenia through campaigns. They are providing funding for R&D of novel treatment options. Various regulations are framed for approval and marketing of sarcopenia drugs and supplements.

Economic: Rising geriatric population suffering from sarcopenia is fueling the market growth. However, high cost of branded drugs can hinder the market.

Social: Changing lifestyle with lack of physical activity is increasing the risk of sarcopenia. Also, increasing obesity rates can exacerbate sarcopenia.

Technological: Biomarkers and imaging tools are being developed for early diagnosis of sarcopenia. Researchers are conducting clinical trials to develop cure for sarcopenia utilizing stem cell therapy and gene therapy.

Key Takeaways

The Global Sarcopenia Treatment Market Demand is expected to witness high growth.

North America holds the largest market share currently due to presence of major players and higher healthcare expenditure. However, Asia Pacific is poised to register fastest growth over the forecast period supported by rising geriatric population, growing obesity, changing lifestyle in developing nations and increased awareness.

Key players operating in the sarcopenia treatment market are Yokogawa, General Electric, Rockwell Automation, MAVERICK Technologies, Emerson, Siemens, Rudolph Technologies, Honeywell International, ABB, Schneider Electric, Aspen Technology. Key players are focusing on new product launches and partnerships for expanding their presence and gaining competitive edge in sarcopenia treatment market. Strategic collaborations are helping key players to develop advanced treatment options for sarcopenia.

*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it